Clinical Trials Browser

Phase 1 × Neoplasm, Residual × NKTR-255 × Clear all

NCT03233854 2025-11-18

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Phase 1 Active not recruiting

Burkitt Lymphoma, Neoplasm, Residual